Unitech Biotech’s net profit in 2019 is 406,100 to convert losses into profit, and the gross profit rate of the products is higher than last year.

Original title: Unitech Biotech’s net profit for 2019 of 406,100 to convert losses into profit, the gross profit margin of the product increased compared to last year

On April 25, Unitech (831936) recently released 2019Annual report,AdIt shows that during the reporting period, you earned income of RMB 34,121,509.82,I andIt fell 17.64%; attributable to listingThe companyShareholdersOfNet profitRMB 406,055.44, which turned into a profit compared to the same period of the previous year; Basic earnings per share were RMB 0.02 and -0.11 yuan in the same period last year.

It is understood thatOperating incomeThe main reason: the company is in the sales transformation period.AgentproductsSales gradually change to autonomySale of productsMainly, the company gave up on imports that overlap with self-developed products.Product lineThe top-tier agency authority primarily promotes independent products and implements national substitution. Because abroadBrandHas won in ChinaClientRecognize that it is still a process for independent R&D products to form a comprehensive replacement. Although operating income decreased significantly, the proportion of own products increased by 42% year-over-year.Interest rateCompared to last year’s 21.57% increase, the company’s products are more competitive and its profitability is gradually strengthening. The transformation of the company’s sales strategy is primarily to reduce its dependence on foreign agent brands and vigorously develop its ownMain brandTo improve the competitiveness of the company and strengthen sustainability.Development capacity, Which greatly promotes the long-term development of the company.

Short termBorrowThe 37.50% year-over-year decrease was mainly due toBankDebt has been reduced by 3 million yuan, the company’s various management cost optimizations are gradually decreasing, and profitability is improving.

Intangible assets increased 126.49% yoy, primarily as the company increased investment in research and development during the reporting period. There were multiple projects on the fluorescent protein labeling platform, the ELISA antibody development platform, and the flow antibody labeling platform.

Accounts payable increased by 26.18% year-on-year, mainly due to the company’s stable acquisition, upstreamProviderDiceCreditThe account period is extended, the companySupply chainWell managed

InvestmentPropertyThe 100% annual decrease was primarily due to the revitalization of the company’s assets during the reporting period. The company will be located in the Huangpu District Office Building in Shanghai for sale.

The data shows that Unitech is a national high-tech specialized in research, development, production, sales and service of detection reagents related to cell biology and immunology.Business.

(Editor in charge: DF529)